09/14/2021 LAKEWOOD, Colo., Sept. 14, 2021 (GLOBE NEWSWIRE) — Mesa Laboratories, Inc. (NASDAQ:MLAB) (“we”, “us”, “our”, “Mesa” or the “Company”), a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, announced today that it has entered into a definitive agreement to acquire Agena Bioscience,... Read more
San Diego, CA, November 1, 2018 – Agena Bioscience, a global provider of molecular testing solutions, today announced the release of the Chimeric ID Panel designed to reduce the time and cost of performing chimerism analysis for bone marrow engraftment monitoring studies. The SNP-based panel is designed for research use with the MassARRAY® system and is... Read more
23 October 2018 San Diego, CA and Guangzhou, China, Wednesdy, October 24, 2018 – Agena Bioscience (Agena) and DaRui Biotechnolog (DaRui) announced today that the MassARRAY® System has formally passed the registration application of Guangdon Food and Drug Administration, becoming the first CFDA approved MALDI-TOF mass spectrometry system to directly detect nucleic acids for in vitro diagnostics in... Read more
21 August 2018 Combining LabChip® GX Touch Nucleic Acid Analyzer and MassARRAY® for Optimized Liquid Biopsy Workflow San Diego, CA – Agena Bioscience (Agena) announced today that they have entered into a collaboration with PerkinElmer, incorporating the LabChip® GX Touch™ nucleic acid analyzer for quality assessment and quantitation of DNA in the upfront workflow of Agena’s MassARRAY®system. The... Read more
San Diego, CA, July 24, 2018 – Agena Bioscience, a global provider of molecular testing solutions, announced today that it has been selected for participation in the CANCER-ID Consortium. Agena’s MassARRAY® System will support mutation detection from liquid biopsy samples as part of the consortium’s key work packages in lung cancer and breast cancer. “We are... Read more
San Diego, CA, July 10, 2018 – Agena Bioscience announced today that it has entered into a commercial partnership agreement with Zhejiang Dian Diagnostics Co., Ltd (“Dian”), one of China’s largest independent medical laboratories provider. The strategic agreement will enable Dian to promote and broadly commercialize Agena’s MassARRAY® System and DNA testing applications and products throughout... Read more
26 March 2018 San Diego, Calif., and Nanjing, JiangSu, March 26, 2018 – Agena Bioscience (Agena) and Simcere Diagnostics (Simceredx), the subsidiary of SIMCERE Pharmaceutical Group, announced today the signing of a strategic partnership agreement focusing on expanding the use of Agena’s MassARRAY® System for companion diagnostics and pharmacogenetic testing in China. As a leading pharmaceutical... Read more
The collaboration will focus on results interpretation for cancer genomics. SAN DIEGO, Oct. 5, 2017 /PRNewswire/ — Agena Bioscience, a global provider of molecular genetic solutions and N-of-One Inc., a leader in molecular decision support for oncology, have teamed together to provide interpretation of cancer genomic data generated by the MassARRAY® System. This strategic partnership supports the expansion... Read more